Results 51 to 60 of about 15,436 (169)

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Acoramidis in Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine
To the Editor: In a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy, Gillmore et al. (Jan. 11 issue)(1) used the Finkelstein-Schoenfeld test to assess the hierarchical composite primary outcome. They expressed the treatment effect as a win ratio, thereby following the initial presentation of the analysis of a prioritized outcome.(2)
VERBEECK, Johan, De Backer, Mickael, BUYSE, Marc   +2 more
openaire   +5 more sources

Role of FibroScan in evaluating hepatic involvement in systemic amyloidosis: a single‐centre prospective pilot study

Internal Medicine Journal, EarlyView.
Abstract Background Amyloidosis encompasses a group of diseases characterised by extracellular deposition of misfolded protein fibrils, potentially leading to organ dysfunction. Liver involvement occurs via direct amyloid infiltration, common in immunoglobulin light chain (AL) amyloidosis, or congestive hepatopathy, more typical in transthyretin (ATTR)
M Tang, N Vootukuru, J Tjahyadi, D Clayton Chubb, H Jina, SB Ting, S Bloom, R Sawhney, S Gibbs, O. Niewiadomski   +9 more
wiley   +1 more source

Inotersen therapy of transthyretin amyloid cardiomyopathy [PDF]

Amyloid, 2019
Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense ...
Noel R, Dasgupta, Stacy M, Rissing, Jessica, Smith, Jeesun, Jung, Merrill D, Benson   +4 more
openaire   +2 more sources

Description of rare clinical case of AA-amyloidosis with involvement in pathological process of heart and lungs

Инновационная медицина Кубани, 2020
Amyloidosis is a unique group of disorders caused by the insoluble protein fibers accumulation known as amyloid fibrils in extracellular tissue and organ spaces.
Z. G. Tatarintseva, E. D. Kosmacheva
doaj   +1 more source

Feasibility, Safety, and Efficacy of Pulsed Field Ablation for Ventricular Arrhythmias: Insights From a Large Health System Registry in the United States

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Pulsed field ablation (PFA) is an emerging non‐thermal ablation modality with proven safety in atrial arrhythmia ablation. However, data on its performance for ventricular arrhythmias (VA) remain limited. Objective To evaluate the feasibility, safety, and efficacy of PFA for complex VA in a multicenter real‐world US registry ...
Narut Prasitlumkum, Juan F. Rodriguez‐Riascos, Hema Vemulapalli, Aakash Somappa, Camilo A. Estrada‐Vargas, Olubadewa A. Fatunde, Carlos A. Rojas, Poojan Prajapati, Keerthika Vijayakumar, Suraj Kapa, Duy Nguyen, Samuel Asirvatham, Malini Madhavan, Christopher McLeod, Hicham Z. El Masry, Abhishek J. Deshmukh, Danesh K. Kella, Ammar M. Killu, Siva K. Mulpuru, Mayank Sardana, Luis R. Scott, Alan M. Sugrue, Komandoor Srivathsan   +22 more
wiley   +1 more source

High profile transvalvular microaxial flow pump as a bridge to heart transplantation for amyloid cardiomyopathy: A case series

JHLT Open
Background: The definitive treatment for end-stage heart failure (ESHF) due to amyloid cardiomyopathy (ACM) is an orthotopic heart transplant (OHT).
Pankaj Garg, MBBS, Mohammad Alomari, MD, Ishaq Wadiwala, MBBS, Melissa Lyle, MD, Si Pham, MD, Nafiye Busra Celik, MD, Juan C. Leoni Moreno, MD, Rohan Goswami, MD, Kevin Landolfo, MD, Jose Nativi-Nicolau, MD, Daniel Yip, MD, Parag C. Patel, MD, Basar Sareyyupoglu, MD   +12 more
doaj   +1 more source

Review of cardiac amyloidosis

Journal of the Practice of Cardiovascular Sciences, 2018
Cardiac amyloidosis is characterized by clinically significant extracellular amyloid infiltration of the heart that is commonly associated with multiorgan involvement depending on the type of amyloid.
Srikant Shivan, Sandeep Seth
doaj   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Inpatient Cardiac Resynchronization Therapy During Heart Failure Hospitalization: A Distinct High‐Risk Phenotype

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common.
Oliver Rees, James Dargan, Jemima Weir, Robin Ray, Giuseppe Rosano, Fadi Johura   +5 more
wiley   +1 more source